Intercellular transfer of exosomal wild type EGFR triggers osimertinib resistance in non-small cell lung cancer

Volume: 20, Issue: 1
Published: Jan 18, 2021
Abstract
Background Epidermal growth factor receptor (EGFR)-mutated lung cancer constitutes a major subgroup of non-small cell lung cancer (NSCLC) and osimertinib is administrated as first-line treatment. However, most patients with osimertinib treatment eventually relapse within one year. The underlying mechanisms of osimertinib resistance remain largely unexplored. Methods Exosomes isolation was performed by differential centrifugation. Co-culture...
Paper Details
Title
Intercellular transfer of exosomal wild type EGFR triggers osimertinib resistance in non-small cell lung cancer
Published Date
Jan 18, 2021
Volume
20
Issue
1
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.